The global carcinoid syndrome diarrhea treatment market was valued at USD 4.63 billion in 2025 and is projected to grow from USD 5.02 billion in 2026 to USD 9.57 billion by 2034, registering a CAGR of 8.4% during 2026–2034. North America dominated the market with a 41.6% share in 2025, while Asia Pacific is expected to register the fastest CAGR of 8.12% during the forecast period.
Market Size (2025): USD 4.63 Billion
Market Size (2026): USD 5.02 Billion
CAGR (Forecast Period): 8.4% during 2026–2034
Forecast Year: 2034
Projected Market Size (2034): USD 9.57 Billion
Dominant Region: North America – 41.6% share in 2025
Fastest Growing Region: Asia Pacific – 8.12% CAGR
Market Overview
Carcinoid syndrome diarrhea treatment comprises therapies used to manage persistent diarrhea associated with carcinoid syndrome, a condition linked to neuroendocrine tumors that release excessive hormones such as serotonin. The treatment landscape includes somatostatin analogs, serotonin-targeted therapies, supportive medications, and emerging targeted approaches used across hospitals, specialty clinics, and oncology centers.
Market expansion is supported by greater diagnosis of neuroendocrine tumors, advances in targeted treatments, and improving access to specialized cancer care. The treatment landscape is also evolving toward therapies that address the underlying mechanisms responsible for persistent diarrhea and provide more convenient long-term symptom management.
Growth Drivers
Loss of response to long-term somatostatin analog therapy is creating a need for additional treatment options. Some patients experience breakthrough diarrhea despite continuing therapy, encouraging the use of add-on medicines, dose adjustments, and targeted approaches to maintain symptom control. In March 2026, updated clinical information continued to highlight loss of response during prolonged somatostatin analog treatment, reinforcing the need for additional diarrhea-control strategies.
The development of oral therapies is also broadening treatment options for patients who rely on long-acting injectable therapies. In November 2025, Crinetics Pharmaceuticals randomized the first patient in the Phase 3 CAREFNDR trial evaluating once-daily oral paltusotine for carcinoid syndrome, with the study assessing bowel-movement frequency and flushing episodes.
Market Challenges
Treatment-related gastrointestinal effects can complicate long-term symptom management because patients may already experience substantial gastrointestinal symptoms from carcinoid syndrome. Somatostatin analog therapy can contribute to pancreatic exocrine insufficiency and diarrhea, while serotonin-targeted treatments may cause constipation and abdominal discomfort, requiring clinicians to distinguish treatment-related effects from disease symptoms.
The small patient population associated with carcinoid syndrome also makes large clinical trials difficult. Patient recruitment requires appropriate tumor characteristics, active symptoms, and consideration of previous somatostatin analog use and other causes of diarrhea, which can increase development complexity and costs.
Market Opportunities
Broader availability of therapies targeting neuroendocrine tumors creates opportunities for integrated treatment portfolios. Companies can combine medicines addressing the underlying tumor with therapies designed to control carcinoid syndrome symptoms, creating complementary treatment pathways for patients requiring both tumor management and symptom control.
In July 2025, Ipsen received European Commission approval for Cabometyx for previously treated advanced neuroendocrine tumors, expanding systemic treatment options for NET patients alongside its established Somatuline portfolio. Such developments create opportunities for pharmaceutical companies to strengthen integrated oncology and symptom-management offerings.
Segment Analysis
By treatment type, the somatostatin analog (SSA) therapy segment dominated the carcinoid syndrome diarrhea treatment market with a 49.8% share in 2025, valued at USD 2.31 billion. SSAs remain widely used for controlling hormone secretion and managing symptoms associated with carcinoid syndrome, supporting their leading position.
By distribution channel, hospital pharmacies accounted for the largest share in 2025 at 52.4%, with a market value of USD 2.43 billion. Meanwhile, the online pharmacies segment is projected to register the fastest growth at a CAGR of 8.34% during 2026–2034, supported by digital healthcare services, home delivery, and improved access to specialty medicines.
By end user, hospitals dominated the market with a 57.6% share in 2025, valued at USD 2.67 billion. Specialized oncology services, multidisciplinary treatment teams, and advanced diagnostic and therapeutic facilities support the segment's leading position. Cancer research institutes are expected to register the fastest growth at a CAGR of 7.48% during the forecast period.
Regional Analysis
North America held the largest position in the carcinoid syndrome diarrhea treatment market, accounting for a 41.6% share in 2025, equivalent to USD 1.93 billion. The region benefits from established healthcare infrastructure, specialized oncology services, favorable reimbursement conditions, and strong clinical research activity. The U.S. represents the largest market in the region, while Canada is supported by improving access to oncology care and rare-disease treatment.
Asia Pacific is projected to register the fastest regional CAGR of 8.12% during 2026–2034, accounting for 19.8% of the global market in 2025. Improving healthcare infrastructure, greater awareness of rare cancers, expanding access to advanced therapies, and rising healthcare expenditure are supporting growth across Japan, China, India, and other regional markets.
Europe accounted for 27.4% of the global market in 2025, while Latin America and the Middle East & Africa represented 6.3% and 4.9%, respectively. Specialized oncology services, rare-disease awareness, healthcare investment, and improved access to advanced treatments are supporting market development across these regions.
Competitive Landscape
The carcinoid syndrome diarrhea treatment market includes pharmaceutical companies developing somatostatin analogs, serotonin-targeted therapies, supportive treatments, and broader neuroendocrine tumor therapies. Competition is shaped by therapeutic efficacy, symptom-control capabilities, treatment convenience, clinical development, regulatory approvals, and access to specialized oncology markets.
Key companies include:
Lexicon Pharmaceuticals Inc.
Novartis International AG (Sandoz)
Pharmascience Inc.
Omega Laboratories Ltd.
Teva Pharmaceutical Industries Ltd.
Mylan N.V.
Ipsen Biopharmaceuticals Inc.
Sirtex Medical Limited
BTG International Ltd.
Wockhardt Ltd.
Recent Developments
In May 2026, TerSera Therapeutics advanced its oncology supportive-care portfolio with treatments for carcinoid syndrome symptoms, including therapies targeting hormone-related diarrhea management. In March 2026, Ipsen strengthened clinical support programs for Somatuline (lanreotide), which is used to manage neuroendocrine tumor-related symptoms, including carcinoid syndrome.
In December 2025, Novartis advanced long-acting somatostatin analog therapies for symptom control associated with carcinoid syndrome. In September 2025, TerSera Therapeutics expanded the availability of Xermelo (telotristat ethyl) for patients with carcinoid syndrome diarrhea that remains uncontrolled despite somatostatin analog therapy.
Click to Read the Complete Insights & Report: https://straitsresearch.com/report/carcinoid-syndrome-diarrhea-treatment-market
Future Outlook
The carcinoid syndrome diarrhea treatment market is expected to expand through 2034 as diagnosis of neuroendocrine tumors improves and targeted therapies become more accessible. Continued development of oral therapies, serotonin-targeted treatments, and complementary symptom-management approaches is expected to broaden treatment options for patients with persistent diarrhea.
Asia Pacific is expected to remain the fastest-growing regional market, while North America retains its leading position. Pharmaceutical companies are likely to focus on treatment convenience, sustained symptom control, integrated neuroendocrine tumor management, and specialized therapies for patients whose symptoms remain inadequately controlled with existing treatment approaches.
About Straits Research
Straits Research is a global market intelligence and consulting company providing industry research, strategic insights, customized consulting, and business intelligence solutions across diverse markets and industries.
Top comments (0)